Stephen J Bagley, Arati S Desai, MacLean P Nasrallah, Donald M O'Rourke
{"title":"Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.","authors":"Stephen J Bagley, Arati S Desai, MacLean P Nasrallah, Donald M O'Rourke","doi":"10.1097/RMR.0000000000000233","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma (GBM) is the deadliest form of brain cancer and recurs uniformly. Despite aggressive treatment with maximal safe surgical resection, adjuvant radiation with temozolomide chemotherapy, and alternating electrical field therapy, median survival for newly diagnosed GBM remains <2 years. Novel therapies are desperately needed. Immunotherapy, which has led to significant improvement in patient outcomes across many tumor types, is currently being studied in a large number of GBM clinical trials. One of the biggest challenges in immunotherapy trials in GBM has been accurate response assessment using currently available imaging modalities, including magnetic resonance imaging. In this review, we will discuss the rationale for immunotherapy for GBM, immunotherapeutic modalities currently under clinical evaluation in GBM, and the challenges and recent advances in imaging response assessment in GBM immunotherapy.</p>","PeriodicalId":39381,"journal":{"name":"Topics in Magnetic Resonance Imaging","volume":"29 2","pages":"95-102"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/RMR.0000000000000233","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Topics in Magnetic Resonance Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/RMR.0000000000000233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5
Abstract
Glioblastoma (GBM) is the deadliest form of brain cancer and recurs uniformly. Despite aggressive treatment with maximal safe surgical resection, adjuvant radiation with temozolomide chemotherapy, and alternating electrical field therapy, median survival for newly diagnosed GBM remains <2 years. Novel therapies are desperately needed. Immunotherapy, which has led to significant improvement in patient outcomes across many tumor types, is currently being studied in a large number of GBM clinical trials. One of the biggest challenges in immunotherapy trials in GBM has been accurate response assessment using currently available imaging modalities, including magnetic resonance imaging. In this review, we will discuss the rationale for immunotherapy for GBM, immunotherapeutic modalities currently under clinical evaluation in GBM, and the challenges and recent advances in imaging response assessment in GBM immunotherapy.
期刊介绍：
Topics in Magnetic Resonance Imaging is a leading information resource for professionals in the MRI community. This publication supplies authoritative, up-to-the-minute coverage of technical advances in this evolving field as well as practical, hands-on guidance from leading experts. Six times a year, TMRI focuses on a single timely topic of interest to radiologists. These topical issues present a variety of perspectives from top radiological authorities to provide an in-depth understanding of how MRI is being used in each area.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
